BEIJING GOBROAD HOSPITAL
BEIJING GOBROAD HOSPITAL — Beijing
Hospital Profile
Beijing Gaobo Hospital is a research-oriented hospital with strategic goals of diagnosing and treating complex and severe diseases, conducting clinical research, and translating biotechnology, pharmaceuticals, and medical devices into practical applications. It also serves as a public service platform for clinical research in Beijing and is one of the flagship hospitals of Gaobo Medical Group. The hospital is located in the Life Science Industrial Park of Changping District, Beijing, with a building area of approximately 100,000 square meters and planned 500 beds (including 100 beds for early-stage research patients), officially completed in July 2023. Specializing in solid tumors, hematologic tumors, and brain science, the hospital currently offers comprehensive specialized medical services including melanoma and sarcoma internal medicine & urologic oncology internal medicine, digestive oncology, thoracic oncology, hematologic tumor immunotherapy, lymphoma and myeloma, and brain science. In January 2024, it became an affiliated hospital of China Pharmaceutical University, leveraging the university's high-quality talent training and cutting-edge scientific research advantages to promote the translation of new drug development achievements.
Medical Milestones
Officially completed in July 2023; in January 2024, it became an affiliated hospital of China Pharmaceutical University. Gaobo Medical Group was established in 2017, and since its establishment, it has cumulatively served hundreds of innovative drug trials for hundreds of innovative drug companies, as well as bringing hope of life to tens of thousands of patients with difficult and severe diseases.
Key Capabilities & Patient Care
The hospital has brought together a group of top Chinese clinical research experts and a complete clinical research support team. Based on clinical research capabilities, it integrates Beijing's abundant resources in basic research, start-up enterprises, and research institutions to build a high-level medical innovation ecosystem. Gaobo Medical Group has four major business divisions: the Center for Complex and Severe Diseases, the Clinical Research Center, the Precision Diagnosis Center, and the Data Intelligence Center. With the mission of promoting medical innovation, it gathers clinical experts and establishes a platform that integrates industry and clinical practice. More than half of the team provides professional services for clinical innovation transformation, and it has established specialized service teams for early clinical research, central laboratories, central imaging, central pathology, cardiac safety evaluation, clinical pharmacology, medicine, and statistics.
Advanced Technology
The building area is approximately 100,000 square meters, covering departments such as Melanoma and Sarcoma Internal Medicine & Urologic Oncology, Gastrointestinal Oncology, Thoracic Oncology, Hematologic Oncology Immunotherapy, Lymphoma and Myeloma, Neuroscience, etc. Data Statistics: • Bed capacity: Planned 500 beds (including 100 Phase I research beds) • Number of departments: Three main directions: solid tumors, hematologic tumors, and neuroscience; 6 specialized treatment departments already listed • Number of full-time physicians: Gathering high-level clinical research experts + complete research support team; number not disclosed • Number of multi-site practitioners / specially appointed experts: Total number not publicly disclosed; verifiable: Chief Scientist Shen Lin (Director of Gastrointestinal Oncology, Peking University Cancer Hospital; Director of Phase I Clinical Trial Ward) • Annual outpatient volume: (As a research-oriented hospital focusing on clinical research, regular outpatient volume not disclosed) • Surgical capability: Focused on the diagnosis and treatment of complex and severe cases and clinical trials; support teams include Phase I Clinical Research Center, central laboratory, central imaging, central pathology, etc. • International certifications and qualifications: Obtained GCP certification in October 2023; included as a designated medical institution; affiliated hospital of China Pharmaceutical University; capable of hosting multi-center global clinical trials • International services: Complies with international standards and capable of hosting multi-center global clinical trials